

Resource Summary Report

Generated by [RRID](#) on Aug 17, 2026

pcDNA3.3-SARS2-B.1.617.2

RRID:Addgene_172320

Type: Plasmid

Proper Citation

RRID:Addgene_172320

Plasmid Information

URL: <http://www.addgene.org/172320>

Proper Citation: RRID:Addgene_172320

Insert Name: Spike of B.1.617.2 strain

Organism: SARS-CoV-2

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:34519517](#)

Vector Backbone Description: Backbone Size:5500; Vector Backbone:pcDNA3.3; Vector Types:Mammalian Expression; Bacterial Resistance:Ampicillin

Plasmid Name: pcDNA3.3-SARS2-B.1.617.2

Relevant Mutation: T19R, 156G, 157-158del, L452R, T478K, D614G, P681R, D950N, c-terminal 18aa deletion

Record Creation Time: 20220422T222000+0000

Record Last Update: 20260815T081023+0000

Ratings and Alerts

No rating or validation information has been found for pcDNA3.3-SARS2-B.1.617.2.

No alerts have been found for pcDNA3.3-SARS2-B.1.617.2.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 37 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Finicle BT, et al. (2026) Endolysosomal trafficking regulator SH-BC-893 inhibits coronavirus entry in vitro and in vivo. *Scientific reports*, 16(1).

Sulea T, et al. (2026) Multifunctional ACE2-nanobody fusion design for pan-specific neutralization and cardiovascular protection in SARS coronavirus infection. *Antimicrobial agents and chemotherapy*, 70(5), e0002426.

Dislers A, et al. (2026) Immunogenicity of SARS-CoV-2 vaccine prototype based on virus-like particles of hepatitis B core antigen from genotype G and interleukin 12 expressing Semliki Forest virus as a genetic adjuvant. *The Journal of general virology*, 107(3).

Chai T, et al. (2026) Elucidating genes sufficient for viral entry into cells through sequential genome-wide CRISPR activation screens. *bioRxiv : the preprint server for biology*.

Hwang J, et al. (2025) Fc-binding nanodisc restores antiviral efficacy of antibodies with reduced neutralizing effects against evolving SARS-CoV-2 variants. *Journal of nanobiotechnology*, 23(1), 44.

Ramasamy S, et al. (2025) Serological Assays Reveal No Evidence of Natural SARS-CoV-2 Infection in US Cattle. *Microorganisms*, 13(3).

Lu J, et al. (2025) Identifying Exifone as a Dual-Target Agent Targeting Both SARS-CoV-2 3CL Protease and the ACE2/S-RBD Interaction Among Clinical Polyphenolic Compounds. *International journal of molecular sciences*, 26(5).

Hwang J, et al. (2025) Broad-Spectrum Antiviral Styrene Maleic-Acid Copolymer Lipid Particle Nanodiscs for pH-Responsive Irreversible Virus Inactivation. *Biomacromolecules*, 26(7), 4051.

Vařová V, et al. (2025) Long-Term Dynamics of SARS-CoV-2 Variant-Specific Neutralizing Antibodies Following mRNA Vaccination and Infection. *Viruses*, 17(5).

Zúñiga R, et al. (2025) Bromhexine inhibits SARS-CoV-2 Omicron and variant pseudovirus infection via ACE2-targeted mechanisms. *Frontiers in pharmacology*, 16, 1745277.

Jung I, et al. (2025) Rapid Discovery of Potent Neutralizing Antibodies against SARS-CoV-2 through Directed Evolution of SARS-CoV-1 Antibodies. *Molecular pharmaceutics*, 22(9), 5316.

Jana ID, et al. (2025) Early 2022 breakthrough infection sera from India target the conserved cryptic class 5 epitope to counteract immune escape by SARS-CoV-2 variants. *Journal of virology*, 99(4), e0005125.

Shukla N, et al. (2024) Pseudotyped virus infection of multiplexed ACE2 libraries reveals SARS-CoV-2 variant shifts in receptor usage. *PLoS pathogens*, 20(5), e1012044.

Thümmeler L, et al. (2024) Fluoxetine and Sertraline Potently Neutralize the Replication of Distinct SARS-CoV-2 Variants. *Viruses*, 16(4).

Connor RI, et al. (2024) Characteristics and Functions of Infection-enhancing Antibodies to the N-terminal Domain of SARS-CoV-2. *Pathogens & immunity*, 9(2), 1.

Manu AA, et al. (2024) Development and utility of a SARS-CoV-2 pseudovirus assay for compound screening and antibody neutralization assays. *Heliyon*, 10(10), e31392.

Eden T, et al. (2024) Generation of nanobodies from transgenic 'LamaMice' lacking an endogenous immunoglobulin repertoire. *Nature communications*, 15(1), 4728.

Chawansuntati K, et al. (2024) Safety and immunogenicity of CoronaVac and ChAdOx1 heterologous prime-boost vaccines in an overweight population in Chiang Mai, Thailand. *Vaccine: X*, 18, 100475.

Shukla N, et al. (2024) Pseudotyped virus infection of multiplexed ACE2 libraries reveals SARS-CoV-2 variant shifts in receptor usage. *bioRxiv : the preprint server for biology*.

Xiang Y, et al. (2023) Ginkgolic acids inhibit SARS-CoV-2 and its variants by blocking the spike protein/ACE2 interplay. *International journal of biological macromolecules*, 226, 780.